{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38362086", "DateRevised": {"Year": "2024", "Month": "02", "Day": "17"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1039/d3ra08962b"], "ArticleDate": [{"Year": "2024", "Month": "02", "Day": "14"}], "Journal": {"ISSN": "2046-2069", "JournalIssue": {"Volume": "14", "Issue": "9", "PubDate": {"Year": "2024", "Month": "Feb", "Day": "14"}}, "Title": "RSC advances", "ISOAbbreviation": "RSC Adv"}, "ArticleTitle": "Antineoplastic indole-containing compounds with potential VEGFR inhibitory properties.", "Pagination": {"StartPage": "5690", "EndPage": "5728", "MedlinePgn": "5690-5728"}, "Abstract": {"AbstractText": ["Cancer is one of the most significant health challenges worldwide. Various techniques, tools and therapeutics/materials have been developed in the last few decades for the treatment of cancer, together with great interest, funding and efforts from the scientific society. However, all the reported studies and efforts seem insufficient to combat the various types of cancer, especially the advanced ones. The overexpression of tyrosine kinases is associated with cancer proliferation and/or metastasis. VEGF, an important category of tyrosine kinases, and its receptors (VEGFR) are hyper-activated in different cancers. Accordingly, they are known as important factors in the angiogenesis of different tumors and are considered in the development of effective therapeutic approaches for controlling many types of cancer. In this case, targeted therapeutic approaches are preferable to the traditional non-selective approaches to minimize the side effects and drawbacks associated with treatment. Several indole-containing compounds have been identified as effective agents against VEGFR. Herein, we present a summary of the recent indolyl analogs reported within the last decade (2012-2023) with potential antineoplastic and VEGFR inhibitory properties. The most important drugs, natural products, synthesized potent compounds and promising hits/leads are highlighted. Indoles functionalized and conjugated with various heterocycles beside spiroindoles are also considered."], "CopyrightInformation": "This journal is \u00a9 The Royal Society of Chemistry."}, "AuthorList": [{"Identifier": ["0000-0003-0038-0835"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pesticide Chemistry, National Research Centre Dokki Giza 12622 Egypt girgisas10@yahoo.com as.girgis@nrc.sci.eg."}], "LastName": "Aboshouk", "ForeName": "Dalia R", "Initials": "DR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science, Helwan University Helwan Egypt."}], "LastName": "Youssef", "ForeName": "M Adel", "Initials": "MA"}, {"Identifier": ["0000-0001-9242-0798"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pesticide Chemistry, National Research Centre Dokki Giza 12622 Egypt girgisas10@yahoo.com as.girgis@nrc.sci.eg."}], "LastName": "Bekheit", "ForeName": "Mohamed S", "Initials": "MS"}, {"Identifier": ["0000-0003-2691-7725"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry of Medicinal Plants Department, National Research Centre Dokki Giza 12622 Egypt."}], "LastName": "Hamed", "ForeName": "Ahmed R", "Initials": "AR"}, {"Identifier": ["0000-0003-4407-9745"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pesticide Chemistry, National Research Centre Dokki Giza 12622 Egypt girgisas10@yahoo.com as.girgis@nrc.sci.eg."}], "LastName": "Girgis", "ForeName": "Adel S", "Initials": "AS"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "RSC Adv", "NlmUniqueID": "101581657", "ISSNLinking": "2046-2069"}, "CoiStatement": "There is no conflict to declare."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Zha G.-F. Qin H.-L. Youssif B. G. M. Amjad M. W. Raja M. A. G. Abdelazeem A. H. Bukhari S. N. A. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance. Eur. J. Med. Chem. 2017;135:34\u201348. doi: 10.1016/j.ejmech.2017.04.025.", "ArticleIdList": ["10.1016/j.ejmech.2017.04.025", "28431353"]}, {"Citation": "Chhikara B. S. Parang K. Global cancer statistics 2022: the trends projection analysis. Chem. Biol. Lett. 2023;10:451."}, {"Citation": "Siegel R. L. Miller K. D. Wagle N. S. Jemal A. Cancer statistics, 2023. Ca-Cancer J. Clin. 2023;73:17\u201348. doi: 10.3322/caac.21763.", "ArticleIdList": ["10.3322/caac.21763", "36633525"]}, {"Citation": "Ferlay J. Soerjomataram I. Dikshit R. Eser S. Mathers C. Rebelo M. Parkin D. M. Forman D. Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:359\u2013386. doi: 10.1002/ijc.29210.", "ArticleIdList": ["10.1002/ijc.29210", "25220842"]}, {"Citation": "Penny L. K. Wallace H. M. The challenges for cancer chemoprevention. Chem. Soc. Rev. 2015;44:8836\u20138847. doi: 10.1039/c5cs00705d.", "ArticleIdList": ["10.1039/c5cs00705d", "26595684"]}, {"Citation": "Jha K. T. Shome A. Chahat Chawla P. A. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: biological activity and structural activity relationship. Bioorg. Chem. 2023;138:106680. doi: 10.1016/j.bioorg.2023.106680.", "ArticleIdList": ["10.1016/j.bioorg.2023.106680", "37336103"]}, {"Citation": "Soltan O. M. Shoman M. E. Abdel-Aziz S. A. Narumi A. Konno H. Abdel-Aziz M. Molecular hybrids: a five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. Eur. J. Med. Chem. 2021;225:113768. doi: 10.1016/j.ejmech.2021.113768.", "ArticleIdList": ["10.1016/j.ejmech.2021.113768", "34450497"]}, {"Citation": "Robinson D. R. Wu Y.-M. Lin S.-F. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548\u20135557. doi: 10.1038/sj.onc.1203957.", "ArticleIdList": ["10.1038/sj.onc.1203957", "11114734"]}, {"Citation": "Mondal D. Abdul Amin S. Moinul M. Das K. Jha T. Gayen S. How the structural properties of the indole derivatives are important in kinase targeted drug design?: a case study on tyrosine kinase inhibitors. Bioorg. Med. Chem. 2022;53:116534. doi: 10.1016/j.bmc.2021.116534.", "ArticleIdList": ["10.1016/j.bmc.2021.116534", "34864496"]}, {"Citation": "Srour A. M. Panda S. S. Mostafa A. Fayad W. El-Manawaty M. A. Soliman A. A. F. Moatasim Y. El Taweel A. Abdelhameed M. F. Bekheit M. S. Ali M. A. Girgis A. S. Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Bioorg. Chem. 2021;117:105466. doi: 10.1016/j.bioorg.2021.105466.", "ArticleIdList": ["10.1016/j.bioorg.2021.105466", "PMC8566089", "34775204"]}, {"Citation": "Liang X. Yang Q. Wu P. He C. Yin L. Xu F. Yin Z. Yue G. Zou Y. Li L. Song X. Lv C. Zhang W. Jing B. The synthesis review of the approved Tyrosine kinase inhibitors for anticancer therapy in 2015\u20132020. Bioorg. Chem. 2021;113:105011. doi: 10.1016/j.bioorg.2021.105011.", "ArticleIdList": ["10.1016/j.bioorg.2021.105011", "34091289"]}, {"Citation": "Abuzenadah A. M. Al-Sayes F. Alam S. S. M. Hoque M. Karim S. Hussain I. M. R. Tabrez S. Elucidating antiangiogenic potential of Rauwolfia serpentina: VEGFR-2 targeting-based molecular docking study. Evidence-Based Complementary Altern. Med. 2022:6224666. doi: 10.1155/2022/6224666.", "ArticleIdList": ["10.1155/2022/6224666", "PMC8860507", "35198035"]}, {"Citation": "Farghaly T. A. Al-Hasani W. A. Abdulwahab H. G. An updated patent review of VEGFR-2 inhibitors (2017-present) Expert Opin. Ther. Pat. 2021;31:989\u20131007. doi: 10.1080/13543776.2021.1935872.", "ArticleIdList": ["10.1080/13543776.2021.1935872", "34043477"]}, {"Citation": "T\u00f6r\u00f6k S. D\u00f6me B. Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors. Magy. Onkol. 2012;56:3\u201315.", "ArticleIdList": ["22403757"]}, {"Citation": "Seliem I. A. Panda S. S. Girgis A. S. Tran Q. L. Said M. F. Bekheit M. S. Abdelnaser A. Nasr S. Fayad W. Soliman A. A. F. Sakhuja R. Ibrahim T. S. Abdel-Samii Z. K. M. Al-Mahmoudy A. M. M. Development of isatin-based Schiff bases targeting VEGFR-2 inhibition: synthesis, characterization, antiproliferative properties, and QSAR studies. ChemMedChem. 2022;17:e202200164. doi: 10.1002/cmdc.202200164.", "ArticleIdList": ["10.1002/cmdc.202200164", "35511203"]}, {"Citation": "Sabbah M. Najem A. Krayem M. Awada A. Journe F. Ghanem G. E. RTK inhibitors in melanoma: from bench to bedside. Cancers. 2021;13:1685. doi: 10.3390/cancers13071685.", "ArticleIdList": ["10.3390/cancers13071685", "PMC8038208", "33918490"]}, {"Citation": "Weiss A. Bonvin D. Berndsen R. H. Scherrer E. Wong T. J. Dyson P. J. Griffioen A. W. Nowak-Sliwinska P. Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci. Rep. 2015;5:8990. doi: 10.1038/srep08990.", "ArticleIdList": ["10.1038/srep08990", "PMC4355632", "25758612"]}, {"Citation": "Massey P. R. Okman J. S. Wilkerson J. Cowen E. W. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support. Care Cancer. 2015;23:1827\u20131835. doi: 10.1007/s00520-014-2520-9.", "ArticleIdList": ["10.1007/s00520-014-2520-9", "PMC4414682", "25471178"]}, {"Citation": "Fawazy N. G. Panda S. S. Mostafa A. Kariuki B. M. Bekheit M. S. Moatasim Y. Kutkat O. Fayad W. El-Manawaty M. A. Soliman A. A. F. El-Shiekh R. A. Srour A. M. Barghash R. F. Girgis A. S. Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties. Sci. Rep. 2022;12:13880. doi: 10.1038/s41598-022-17883-9.", "ArticleIdList": ["10.1038/s41598-022-17883-9", "PMC9380671", "35974029"]}, {"Citation": "Begum R. Mamun-Or-Rashid A. N. M. Lucy T. T. Pramanik K. Sil B. K. Mukerjee N. Tagde P. Yagi M. Yonei Y. Potential therapeutic approach of melatonin against omicron and some other variants of SARS-CoV-2. Molecules. 2022;27:6934. doi: 10.3390/molecules27206934.", "ArticleIdList": ["10.3390/molecules27206934", "PMC9609612", "36296527"]}, {"Citation": "Girgis A. S. Panda S. S. Kariuki B. M. Bekheit M. S. Barghash R. F. Aboshouk D. R. Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2. Molecules. 2023;28:6603. doi: 10.3390/molecules28186603.", "ArticleIdList": ["10.3390/molecules28186603", "PMC10537473", "37764378"]}, {"Citation": "Reiter R. J. Sharma R. Simko F. Dominguez-Rodriguez A. Tesarik J. Neel R. L. Slominski A. T. Kleszczynski K. Martin-Gimenez V. M. Manucha W. Cardinali D. P. Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection. Cell. Mol. Life Sci. 2022;79:143. doi: 10.1007/s00018-021-04102-3.", "ArticleIdList": ["10.1007/s00018-021-04102-3", "PMC8858600", "35187603"]}, {"Citation": "Garc\u00eda G. Rodriguez-Rubio M. Mariblanca A. R. de Soto L. M. Garc\u00eda L. D. Villatoro J. M. Parada J. Q. Meseguer E. S. Rosales M. J. Gonz\u00e1lez J. Arribas J. R. Carcas A. J. de la Oliva P. Borobia A. M. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:466. doi: 10.1186/s13063-020-04436-6.", "ArticleIdList": ["10.1186/s13063-020-04436-6", "PMC7267766", "32493475"]}, {"Citation": "Hasan Z. T. Al Atrakji M. Q. Y. M. A. Mehuaiden A. K. The effect of Melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. Int. J. Infect. Dis. 2022;114:79\u201384. doi: 10.1016/j.ijid.2021.10.012.", "ArticleIdList": ["10.1016/j.ijid.2021.10.012", "PMC8506572", "34653660"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB08839, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://www.drugs.com/history/tivorbex.html, (accessed on Dec. 11, 2023)"}, {"Citation": "Bokhtia R. M. Panda S. S. Girgis A. S. Samir N. Said M. F. Abdelnaser A. Nasr S. Bekheit M. S. Dawood A. S. Sharma H. Wade M. Sharma S. K. Ghanim A. M. New NSAID conjugates as potent and selective COX-2 inhibitors: synthesis, molecular modeling and biological investigation. Molecules. 2023;28:1945. doi: 10.3390/molecules28041945.", "ArticleIdList": ["10.3390/molecules28041945", "PMC9965125", "36838932"]}, {"Citation": "\nhttps://www.drugs.com/dosage/delavirdine.html, (accessed on Dec. 11, 2023)"}, {"Citation": "Li G. Wang Y. De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm. Sin. B. 2022;12:1567\u20131590. doi: 10.1016/j.apsb.2021.11.009.", "ArticleIdList": ["10.1016/j.apsb.2021.11.009", "PMC9279714", "35847492"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB13609, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://www.drugs.com/international/umifenovir.html, (accessed on Dec. 11, 2023)"}, {"Citation": "Shuster A. Pechalrieu D. Jackson C. B. Abegg D. Choe H. Adibekian A. Clinical antiviral drug arbidol inhibits infection by SARS-CoV-2 and variants through direct binding to the spike protein. ACS Chem. Biol. 2021;16:2845\u20132851. doi: 10.1021/acschembio.1c00756.", "ArticleIdList": ["10.1021/acschembio.1c00756", "PMC8610013", "34792325"]}, {"Citation": "Wang X. Cao R. Zhang H. Liu J. Xu M. Hu H. Li Y. Zhao L. Li W. Sun X. Yang X. Shi Z. Deng F. Hu Z. Zhong W. Wang M. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discovery. 2020;6:28. doi: 10.1038/s41421-020-0169-8.", "ArticleIdList": ["10.1038/s41421-020-0169-8", "PMC7195821", "32373347"]}, {"Citation": "\nhttps://www.drugs.com/mtm/pindolol.html, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://www.drugs.com/maxalt.html, (accessed on Dec. 11, 2023)"}, {"Citation": "Yu B. Yu D.-Q. Liu H.-M. Spirooxindoles: promising scaffolds for anticancer agents. Eur. J. Med. Chem. 2015;97:673\u2013698. doi: 10.1016/j.ejmech.2014.06.056.", "ArticleIdList": ["10.1016/j.ejmech.2014.06.056", "24994707"]}, {"Citation": "Jin J. Xie Y. Zhang J.-S. Wang J.-Q. Dai S.-J. He W.-f. Li S.-Y. Ashby Jr. C. R. Chen Z.-S. He Q. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resistance Updates. 2023;67:100929. doi: 10.1016/j.drup.2023.100929.", "ArticleIdList": ["10.1016/j.drup.2023.100929", "36739809"]}, {"Citation": "Guida F. M. Santoni M. Conti A. Burattini L. Savini A. Zeppola T. Caricato M. Cascinu S. Tonini G. Santini D. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Crit. Rev. Oncol. Hematol. 2014;92:208\u2013217. doi: 10.1016/j.critrevonc.2014.07.006.", "ArticleIdList": ["10.1016/j.critrevonc.2014.07.006", "25151214"]}, {"Citation": "Zhang L. Zheng Q. Yang Y. Zhou H. Gong X. Zhao S. Fan C. Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents. Eur. J. Med. Chem. 2014;82:139\u2013151. doi: 10.1016/j.ejmech.2014.05.051.", "ArticleIdList": ["10.1016/j.ejmech.2014.05.051", "24904961"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB01268, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://www.drugs.com/history/sutent.html, (accessed on Dec. 11, 2023)"}, {"Citation": "Zheng X. Zhang Y. Zhang L. Xu W. Ma W. Sun R. Zeng H. Synergistic inhibition of sunitinib and ethaselen against human colorectal cancer cells proliferation. Biomed. Pharmacother. 2016;83:212\u2013220. doi: 10.1016/j.biopha.2016.06.040.", "ArticleIdList": ["10.1016/j.biopha.2016.06.040", "27372405"]}, {"Citation": "Leon L. A. Ant\u00f3n-Aparicio L. M. Treatment of sunitinib-induced hypertension in solid tumors by nitric oxid donors. Redox Biol. 2015;5:413\u2013423. doi: 10.1016/j.redox.2015.09.036.", "ArticleIdList": ["10.1016/j.redox.2015.09.036", "28162293"]}, {"Citation": "Thijs A. M. J. van Herpen C. M. L. Verweij V. Pertijs J. van den Broek P. H. H. van der Graaf W. T. A. Rongen G. A. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J. Hypertens. 2015;33:2075\u20132082. doi: 10.1097/HJH.0000000000000662.", "ArticleIdList": ["10.1097/HJH.0000000000000662", "26203967"]}, {"Citation": "Chow L. Q. Eckhardt S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007;25:884\u2013896. doi: 10.1200/JCO.2006.06.3602.", "ArticleIdList": ["10.1200/JCO.2006.06.3602", "17327610"]}, {"Citation": "Li J.-Y. Ren Y.-P. Yuan Y. JI S.-M. Zhou S.-P. Wang L.-J. Mou Z.-Z. Li L. Lu W. Zhou T.-Y. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice. Acta Pharmacol. Sin. 2016;37:930\u2013940. doi: 10.1038/aps.2016.55.", "ArticleIdList": ["10.1038/aps.2016.55", "PMC4933764", "27180983"]}, {"Citation": "Gravina G. L. Mancini A. Marampon F. Colapietro A. Monache S. D. Sferra R. Vitale F. Richardson P. J. Patient L. Burbidge S. Festuccia C. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. J. Hematol. Oncol. 2017;10:5. doi: 10.1186/s13045-016-0377-8.", "ArticleIdList": ["10.1186/s13045-016-0377-8", "PMC5217647", "28057017"]}, {"Citation": "Gravina G. L. Mancini A. Colapietro A. Vitale F. Vetuschi A. Pompili S. Rossi G. Marampon F. Richardson P. J. Patient L. Patient L. Burbidge S. Festuccia C. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumour Biol. 2017;39 doi: 10.1177/1010428317695528.", "ArticleIdList": ["10.1177/1010428317695528", "28639900"]}, {"Citation": "Wang X. Zhang L. O'Neill A. Bahamon B. Alsop D. C. Mier J. W. Goldberg S. N. Signoretti S. Atkins M. B. Wood C. G. Bhatt R. S. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br. J. Cancer. 2013;108:319\u2013326. doi: 10.1038/bjc.2012.591.", "ArticleIdList": ["10.1038/bjc.2012.591", "PMC3566808", "23322198"]}, {"Citation": "Jamadar A. Suma S. M. Mathew S. Fields T. A. Wallace D. P. Calvet J. P. Rao R. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death Dis. 2021;12:947. doi: 10.1038/s41419-021-04248-9.", "ArticleIdList": ["10.1038/s41419-021-04248-9", "PMC8517027", "34650051"]}, {"Citation": "Landi C. Bergantini L. Cameli P. d'Alessandro M. Carleo A. Shaba E. Rottoli P. Bini L. Bargagli E. Idiopathic pulmonary fibrosis serum proteomic analysis before and after nintedanib therapy. Sci. Rep. 2020;10:9378. doi: 10.1038/s41598-020-66296-z.", "ArticleIdList": ["10.1038/s41598-020-66296-z", "PMC7287088", "32523095"]}, {"Citation": "Hilberg F. Tontsch-Grunt U. Baum A. Le A. T. Doebele R. C. Lieb S. Gianni D. Voss T. Garin-Chesa P. Haslinger C. Kraut N. Triple angiokinase inhibitor Nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J. Pharmacol. Exp. Ther. 2018;364:494\u2013503. doi: 10.1124/jpet.117.244129.", "ArticleIdList": ["10.1124/jpet.117.244129", "PMC6040086", "29263244"]}, {"Citation": "Riesco-Martinez M. C. Torre A. S. Garc\u00eda-Carbonero R. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. Expert Opin. Invest. Drugs. 2017;26:1295\u20131305. doi: 10.1080/13543784.2017.1385762.", "ArticleIdList": ["10.1080/13543784.2017.1385762", "28965421"]}, {"Citation": "Kurzrock R. Stewart D. J. Exploring the benefit/risk associated with antiangiogenic agents for the treatment of non\u2013small cell lung cancer patients. Clin. Cancer Res. 2017;23:1137\u20131148. doi: 10.1158/1078-0432.CCR-16-1968.", "ArticleIdList": ["10.1158/1078-0432.CCR-16-1968", "27940520"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB09079, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://www.drugs.com/history/ofev.html, (accessed on Dec. 11, 2023)"}, {"Citation": "da Silva R. F. Banzato T. P. Alves L. F. Carvalho J. E. Agarwal R. Cagnon V. H. A. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals. Cell Tissue Res. 2020;379:407\u2013420. doi: 10.1007/s00441-019-03091-x.", "ArticleIdList": ["10.1007/s00441-019-03091-x", "31473819"]}, {"Citation": "da Silva R. F. Nogueira-Pangrazi E. Kido L. A. Montico F. Arana S. Kumar D. Raina K. Agarwal R. Cagnon V. H. A. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) J. Biomed. Sci. 2017;24:31. doi: 10.1186/s12929-017-0334-z.", "ArticleIdList": ["10.1186/s12929-017-0334-z", "PMC5429557", "28499383"]}, {"Citation": "Khalique S. Banerjee S. Nintedanib in ovarian cancer. Expert Opin. Invest. Drugs. 2017;26:1073\u20131081. doi: 10.1080/13543784.2017.1353599.", "ArticleIdList": ["10.1080/13543784.2017.1353599", "28721753"]}, {"Citation": "Roth G. J. Binder R. Colbatzky F. Dallinger C. Schlenker-Herceg R. Hilberg F. Wollin S.-L. Kaiser R. Nintedanib: from discovery to the clinic. J. Med. Chem. 2015;58:1053\u20131063. doi: 10.1021/jm501562a.", "ArticleIdList": ["10.1021/jm501562a", "25474320"]}, {"Citation": "Rossi A. Latiano T. P. Parente P. Chiarazzo C. Limosani F. Di Maggio G. Maiello E. The potential role of Nintedanid in treating colorectal cancer, Expert Opin. Pharmacother. 2017;18:1153\u20131162. doi: 10.1080/14656566.2017.1346086.", "ArticleIdList": ["10.1080/14656566.2017.1346086", "28649871"]}, {"Citation": "Kim Y. Lee S. J. Lee J. Y. Lee S.-H. Sun J.-M. Park K. An H. J. Cho J. Y. Kang E. J. Lee H.-Y. Kim J. Keam B. Kim H. R. Lee K. E. Choi M. Y. Lee K. H. Ahn M.-J. Clinical trial of Nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01) Cancer. 2017;123:1958\u20131964. doi: 10.1002/cncr.30537.", "ArticleIdList": ["10.1002/cncr.30537", "28102887"]}, {"Citation": "Schliemann C. Gerss J. Wiebe S. Mikesch J.-H. Knoblauch N. Sauer T. Angenendt L. Kewitz T. Urban M. Butterfass-Bahloul T. Edemir S. Vehring K. M\u00fcller-Tidow C. Berdel W. E. Krug U. A phase I dose escalation study of the triple angiokinase inhibitor Nintedanib combined with low-dose cytarabine in elderly patients with acute myeloid leukemia. PLoS One. 2016;11:e0164499. doi: 10.1371/journal.pone.0164499.", "ArticleIdList": ["10.1371/journal.pone.0164499", "PMC5055288", "27716819"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB11885, (accessed on Dec. 11, 2023)"}, {"Citation": "Xie L. Feng Y. Sun J. Fingerprint loss during combination therapy using osimertinib and anlotinib: a case report. J. Clin. Pharm. Ther. 2022;47:248\u2013250. doi: 10.1111/jcpt.13480.", "ArticleIdList": ["10.1111/jcpt.13480", "34240438"]}, {"Citation": "Liang J. Jin Z. Kuang J. Feng H. Zhao Q. Yang Z. Zhan L. Shen B. Yan J. Cai W. Cheng X. Qiu W. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br. J. Cancer. 2021;125:390\u2013401. doi: 10.1038/s41416-021-01340-x.", "ArticleIdList": ["10.1038/s41416-021-01340-x", "PMC8328993", "34088989"]}, {"Citation": "Li S. Anlotinib: a novel targeted drug for bone and soft tissue sarcoma. Front. Oncol. 2021;11:664853. doi: 10.3389/fonc.2021.664853.", "ArticleIdList": ["10.3389/fonc.2021.664853", "PMC8173120", "34094958"]}, {"Citation": "Shen G. Zheng F. Ren D. Du F. Dong Q. Wang Z. Zhao F. Ahmad R. Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 2018;11:120. doi: 10.1186/s13045-018-0664-7.", "ArticleIdList": ["10.1186/s13045-018-0664-7", "PMC6146601", "30231931"]}, {"Citation": "Syed Y. Y. Anlotinib: first global approval. Drugs. 2018;78:1057\u20131062. doi: 10.1007/s40265-018-0939-x.", "ArticleIdList": ["10.1007/s40265-018-0939-x", "29943374"]}, {"Citation": "Qin T. Liu Z. Wang J. Xia J. Liu S. Jia Y. Liu H. Li K. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol. Med. 2020;17:753\u2013767. doi: 10.20892/j.issn.2095-3941.2020.0024.", "ArticleIdList": ["10.20892/j.issn.2095-3941.2020.0024", "PMC7476093", "32944404"]}, {"Citation": "Jia Z.-X. Zhang Z. Li Z. Li A. Xie Y.-N. Wu H.-J. Yang Z.-B. Zhang H.-M. Zhang X.-M. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis. Eur. Rev. Med. Pharmacol. Sci. 2021;25:2331\u20132343. doi: 10.26355/eurrev_202103_25272.", "ArticleIdList": ["10.26355/eurrev_202103_25272", "33755971"]}, {"Citation": "Li D. Chi Y. Chen X. Ge M. Zhang Y. Guo Z. Wang J. Chen J. Zhang J. Cheng Y. Li Z. Liu H. Qin J. Zhu J. Cheng R. Xu Z. Zheng X. Tang P. Gao M. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin. Cancer Res. 2021;27:3567\u20133575. doi: 10.1158/1078-0432.CCR-20-2950.", "ArticleIdList": ["10.1158/1078-0432.CCR-20-2950", "33832949"]}, {"Citation": "Liu Y. Xiao Q. He J. Hu H. Du J. Zhu Y. Chen J. Liu Z. Wang J. Sun L. Xu D. Li J. Liao X. Wang J. Cai Y. Cai C. Jin Z. Wang L. Yuan Y. Ding K. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med. 2022;20:155. doi: 10.1186/s12916-022-02357-6.", "ArticleIdList": ["10.1186/s12916-022-02357-6", "PMC9071922", "35513832"]}, {"Citation": "Syed Y. Y. Surufatinib: first approval. Drugs. 2021;81:727\u2013732. doi: 10.1007/s40265-021-01489-y.", "ArticleIdList": ["10.1007/s40265-021-01489-y", "33788183"]}, {"Citation": "\nhttps://www.drugs.com/history/surufatinib.html, (accessed on Dec. 11, 2023)"}, {"Citation": "Lu X. Yan S. Koral K. A. Chen Z. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Rev. Anticancer Ther. 2021;21:917\u2013926. doi: 10.1080/14737140.2021.1944110.", "ArticleIdList": ["10.1080/14737140.2021.1944110", "34142932"]}, {"Citation": "Xu J. Bai Y. Sun H. Bai C. Jia R. Li Y. Zhang W. Liu L. Huang C. Guan M. Zhou J. Su W. A single-arm, multicenter, open-label phase 2 trial of Surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer. 2021;127:3975\u20133984. doi: 10.1002/cncr.33803.", "ArticleIdList": ["10.1002/cncr.33803", "34355801"]}, {"Citation": "\nhttps://go.drugbank.com/articles/A24188, (accessed on Dec. 11, 2023)"}, {"Citation": "Huang X. Zhu J. Jiang Y. Xu C. Lv Q. Yu D. Shi K. Ruan Z. Wang Y. SU5416 attenuated lipopolysaccharide-induced acute lung injury in mice by modulating properties of vascular endothelial cells. Drug Des., Dev. Ther. 2019;13:1763\u20131772. doi: 10.2147/DDDT.S188858.", "ArticleIdList": ["10.2147/DDDT.S188858", "PMC6536715", "31213766"]}, {"Citation": "Peloquin G. L. Johnston L. Damarla M. Damico R. L. Hassoun P. M. Kolb T. M. SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model. Respir. Res. 2019;20:123. doi: 10.1186/s12931-019-1079-x.", "ArticleIdList": ["10.1186/s12931-019-1079-x", "PMC6580559", "31208454"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB15247, (accessed on Dec. 11, 2023)"}, {"Citation": "Pedersen K. S. Grierson P. M. Picus J. Lockhart A. C. Roth B. J. Liu J. Morton A. Chan E. Huffman J. Liang C. Wang-Gillam A. Tan B. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study. Invest. New Drugs. 2021;39:1298\u20131305. doi: 10.1007/s10637-021-01093-7.", "ArticleIdList": ["10.1007/s10637-021-01093-7", "33738668"]}, {"Citation": "Zhang K. Wang L. Wei A. Jia X. Liu X. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. Thorac. Cancer. 2020;11:1566\u20131577. doi: 10.1111/1759-7714.13430.", "ArticleIdList": ["10.1111/1759-7714.13430", "PMC7262931", "32368855"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB11741, (accessed on Dec. 11, 2023)"}, {"Citation": "Zhang M. Quan H. Fu L. Li Y. Fu H. Lou L. Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells. Thorac. Cancer. 2021;12:1210\u20131218. doi: 10.1111/1759-7714.13902.", "ArticleIdList": ["10.1111/1759-7714.13902", "PMC8046080", "33656275"]}, {"Citation": "S\u00e1nchez-C\u00e9spedes R. Accornero P. Miretti S. Martignani E. Gattino F. Maniscalco L. Gola C. Iussich S. Martano M. Morello E. Buracco P. Aresu L. De Maria R. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models. Vet. Comp. Oncol. 2020;18:117\u2013127. doi: 10.1111/vco.12562.", "ArticleIdList": ["10.1111/vco.12562", "31816142"]}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB16821, (accessed on Dec. 11, 2023)"}, {"Citation": "Burbridge M. F. Bossard C. J. Saunier C. Fejes I. Bruno A. L\u00e9once S. Ferry G. Da Violante G. Bouzom F. Cattan V. Jacquet-Bescond A. Comoglio P. M. Lockhart B. P. Boutin J. A. Cordi A. Ortuno J.-C. Pierr\u00e9 A. Hickman J. A. Cruzalegui F. H. Depil S. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. 2013;12:1749\u20131762. doi: 10.1158/1535-7163.MCT-13-0075.", "ArticleIdList": ["10.1158/1535-7163.MCT-13-0075", "23804704"]}, {"Citation": "Rodon J. Postel-Vinay S. Hollebecque A. Nuciforo P. Azaro A. Cattan V. Marfai L. Sudey I. Brendel K. Delmas A. Malasse S. Soria J.-C. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur. J. Cancer. 2017;81:142\u2013150. doi: 10.1016/j.ejca.2017.05.007.", "ArticleIdList": ["10.1016/j.ejca.2017.05.007", "28624695"]}, {"Citation": "Wang D. Tang F. Wang S. Jiang Z. Zhang L. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor. Cancer Chemother. Pharmacol. 2012;69:173\u2013183. doi: 10.1007/s00280-011-1681-1.", "ArticleIdList": ["10.1007/s00280-011-1681-1", "21638122"]}, {"Citation": "Mao Y. Xia Z. Zhang X. Zong Y. Zhu L. Yuan B. Lu G. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs. Food Chem. Toxicol. 2012;50:1256\u20131270. doi: 10.1016/j.fct.2012.02.007.", "ArticleIdList": ["10.1016/j.fct.2012.02.007", "22343322"]}, {"Citation": "Girgis A. S. Panda S. S. Srour A. M. Abdelnaser A. Nasr S. Moatasim Y. Kutkat O. El Taweel A. Kandeil A. Mostafa A. Ali M. A. Fawzy N. G. Bekheit M. S. Shalaby E. M. Gigli L. Fayad W. Soliman A. A. F. 3-Alkenyl-2-oxindoles: synthesis, antiproliferative and antiviral properties against SARS-CoV-2. Bioorg. Chem. 2021;114:105131. doi: 10.1016/j.bioorg.2021.105131.", "ArticleIdList": ["10.1016/j.bioorg.2021.105131", "PMC8241580", "34243074"]}, {"Citation": "\nhttps://www.drugs.com/mtm/vincristine.html, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB00541, (accessed on Dec. 11, 2023)"}, {"Citation": "Mondal D. Abdul Amin S. Moinul M. Das K. Jha T. Gayen S. How the structural properties of the indole derivatives are important in kinase targeted drug design?: a case study on tyrosine kinase inhibitors. Bioorg. Med. Chem. 2022;53:116534. doi: 10.1016/j.bmc.2021.116534.", "ArticleIdList": ["10.1016/j.bmc.2021.116534", "34864496"]}, {"Citation": "\nhttps://www.drugs.com/mtm/vinblastine.html, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB00570, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB00309, (accessed on Dec. 11, 2023)"}, {"Citation": "Gallardo-Fern\u00e1ndez M. Cerezo A. B. Hornedo-Ortega R. Troncoso A. M. Garcia-Parrilla M. C. Anti-VEGF effect of bioactive indolic compounds and hydroxytyrosol metabolites. Foods. 2022;11:526. doi: 10.3390/foods11040526.", "ArticleIdList": ["10.3390/foods11040526", "PMC8871452", "35206003"]}, {"Citation": "Al-Wahaibi L. H. Mohammed A. F. Abdelrahman M. H. Trembleau L. Youssif B. G. M. Design, synthesis, and biological evaluation of indole-2-carboxamides as potential multi-target antiproliferative agents. Pharmaceuticals. 2023;16:1039. doi: 10.3390/ph16071039.", "ArticleIdList": ["10.3390/ph16071039", "PMC10385579", "37513950"]}, {"Citation": "Elkamhawy A. Ammar U. M. Paik S. Abdellattif M. H. Elsherbeny M. H. Lee K. Roh E. J. Scaffold repurposing of in-house small molecule candidates leads to discovery of first-in-class CDK-1/HER-2 dual inhibitors: in vitro and in silico screening. Molecules. 2021;26:5324. doi: 10.3390/molecules26175324.", "ArticleIdList": ["10.3390/molecules26175324", "PMC8433807", "34500757"]}, {"Citation": "Elkamhawy A. Paik S. Kim H. J. Park J.-H. Londhe A. M. Lee K. Pae A. N. Park K. D. Roh E. J. Discovery of N-(1-(3-fluorobenzoyl)-1H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B. J. Enzyme Inhib. Med. Chem. 2020;35:1568\u20131580. doi: 10.1080/14756366.2020.1800666.", "ArticleIdList": ["10.1080/14756366.2020.1800666", "PMC7470070", "32752896"]}, {"Citation": "Abdelgawad M. A. Hayallah A. M. Bukhari S. N. A. Musa A. Elmowafy M. Abdel-Rahman H. M. Abd El-Gaber M. K. Design, synthesis, molecular modeling, and anticancer evaluation of new VEGFR-2 inhibitors based on the indolin-2-One scaffold. Pharmaceuticals. 2022;15:1416. doi: 10.3390/ph15111416.", "ArticleIdList": ["10.3390/ph15111416", "PMC9698773", "36422546"]}, {"Citation": "Eldehna W. M. Fares M. Ibrahim H. S. Aly M. H. Zada S. Ali M. M. Abou-Seri S. M. Abdel-Aziz H. A. Abou El Ella D. A. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: synthesis, in vitro biological evaluation and molecular docking. Eur. J. Med. Chem. 2015;100:89\u201397. doi: 10.1016/j.ejmech.2015.05.040.", "ArticleIdList": ["10.1016/j.ejmech.2015.05.040", "26071861"]}, {"Citation": "\nhttps://www.cancer.gov/about-cancer/treatment/drugs/fluorouracil, (accessed on Dec. 11, 2023)"}, {"Citation": "Elkaeed E. B. Yousef R. G. Elkady H. Gobaara I. M. M. Alsfouk A. A. Husein D. Z. Ibrahim I. M. Metwaly A. M. Eissa I. H. The assessment of anticancer and VEGFR-2 inhibitory activities of a new 1H-indole derivative: in silico and in vitro approaches. Processes. 2022;10:1391. doi: 10.3390/pr10071391.", "ArticleIdList": ["10.3390/pr10071391"]}, {"Citation": "Saied S. Shaldam M. Elbadawi M. M. Giovannuzzi S. Nocentini A. Almahli H. Salem R. Ibrahim T. M. Supuran C. T. Eldehna W. M. Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. Eur. J. Med. Chem. 2023;259:115707. doi: 10.1016/j.ejmech.2023.115707.", "ArticleIdList": ["10.1016/j.ejmech.2023.115707", "37556946"]}, {"Citation": "Hassan O. M. Mahmood A. A. R. Hamzah A. H. Tahtamouni L. H. Design, synthesis, and molecular docking studies of 5-bromoindole-2-carboxylic acid hydrazone derivatives: in vitro anticancer and VEGFR-2 inhibitory effects. ChemistrySelect. 2022;7:e202203726. doi: 10.1002/slct.202203726.", "ArticleIdList": ["10.1002/slct.202203726"]}, {"Citation": "Zhang J. Liu T. Chen M. Liu F. Liu X. Zhang J. Lin J. Jin Y. Synthesis and biological evaluation of indole-2-carbohydrazide derivatives as anticancer agents with anti-angiogenic and antiproliferative activities. ChemMedChem. 2018;13:1181\u20131192. doi: 10.1002/cmdc.201800033.", "ArticleIdList": ["10.1002/cmdc.201800033", "29637713"]}, {"Citation": "Wang D.-P. Liu K.-L. Li X.-Y. Lu G.-Q. Xue W.-H. Qian X.-H. Mohamed K. Meng F.-H. Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold. Eur. J. Med. Chem. 2021;211:113083. doi: 10.1016/j.ejmech.2020.113083.", "ArticleIdList": ["10.1016/j.ejmech.2020.113083", "33340911"]}, {"Citation": "Qin M. Yan S. Wang L. Zhang H. Tian Y. Zhao Y. Gong P. Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors. Bioorg. Med. Chem. 2017;25:1778\u20131786. doi: 10.1016/j.bmc.2017.01.039.", "ArticleIdList": ["10.1016/j.bmc.2017.01.039", "28190652"]}, {"Citation": "Qin M. Tian Y. Sun X. Yu S. Xia J. Gong P. Zhang H. Zhao Y. Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors. Eur. J. Med. Chem. 2017;139:492\u2013502. doi: 10.1016/j.ejmech.2017.08.031.", "ArticleIdList": ["10.1016/j.ejmech.2017.08.031", "28826084"]}, {"Citation": "Yang T.-H. Lee C.-I. Huang W.-H. Lee A.-R. Synthesis and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors. Molecules. 2017;22:913. doi: 10.3390/molecules22060913.", "ArticleIdList": ["10.3390/molecules22060913", "PMC6152791", "28561780"]}, {"Citation": "Ding L. Tang F. Huang W. Jin Q. Shen H. Wei P. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2013;23:5630\u20135633. doi: 10.1016/j.bmcl.2013.08.037.", "ArticleIdList": ["10.1016/j.bmcl.2013.08.037", "23999040"]}, {"Citation": "Kim M. H. Tsuhako A. L. Co E. W. Aftab D. T. Bentzien F. Chen J. Cheng W. Engst S. Goon L. Klein R. R. Le D. T. Mac M. Parks J. J. Qian F. Rodriquez M. Stout T. J. Till J. H. Won K.-A. Wu X. Yakes F. M. Yu P. Zhang W. Zhao Y. Lamb P. Nuss J. M. Xu W. The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2012;22:4979\u20134985. doi: 10.1016/j.bmcl.2012.06.029.", "ArticleIdList": ["10.1016/j.bmcl.2012.06.029", "22765894"]}, {"Citation": "Patel S. Challagundla N. Rajput R. A. Mishra S. Design, synthesis, characterization and anticancer activity evaluation of deoxycholic acid-chalcone conjugates. Bioorg. Chem. 2022;127:106036. doi: 10.1016/j.bioorg.2022.106036.", "ArticleIdList": ["10.1016/j.bioorg.2022.106036", "35878450"]}, {"Citation": "Dudchak R. Podolak M. Holota S. Szewczyk-Roszczenko O. Roszczenko P. Bielawska A. Lesyk R. Bielawski K. Click chemistry in the synthesis of antibody-drug conjugates. Bioorg. Chem. 2024;143:106982. doi: 10.1016/j.bioorg.2023.106982.", "ArticleIdList": ["10.1016/j.bioorg.2023.106982", "37995642"]}, {"Citation": "Nofal Z. M. Srour A. M. El-Eraky W. I. Saleh D. O. Girgis A. S. Rational design, synthesis and QSAR study of vasorelaxant active 3-pyridinecarbonitriles incorporating 1H-benzimidazol-2-yl function. Eur. J. Med. Chem. 2013;63:14\u201321. doi: 10.1016/j.ejmech.2013.01.042.", "ArticleIdList": ["10.1016/j.ejmech.2013.01.042", "23454530"]}, {"Citation": "Girgis A. S. Kalmouch A. Ellithey M. Synthesis of novel vasodilatory active nicotinate esters with amino acid function. Bioorg. Med. Chem. 2006;14:8488\u20138494. doi: 10.1016/j.bmc.2006.08.041.", "ArticleIdList": ["10.1016/j.bmc.2006.08.041", "16973365"]}, {"Citation": "Ghanim A. M. Girgis A. S. Kariuki B. M. Samir N. Said M. F. Abdelnaser A. Nasr S. Bekheit M. S. Abdelhameed M. F. Almalki A. J. Ibrahim T. S. Panda S. S. Design and synthesis of ibuprofen-quinoline conjugates as potential anti-inflammatory and analgesic drug candidates. Bioorg. Chem. 2022;119:105557. doi: 10.1016/j.bioorg.2021.105557.", "ArticleIdList": ["10.1016/j.bioorg.2021.105557", "34952242"]}, {"Citation": "Panda S. S. Girgis A. S. Thomas S. J. Capito J. E. George R. F. Salman A. El-Manawaty M. A. Samir A. Synthesis, pharmacological profile and 2D-QSAR studies of curcumin-amino acid conjugates as potential drug candidates. Eur. J. Med. Chem. 2020;196:112293. doi: 10.1016/j.ejmech.2020.112293.", "ArticleIdList": ["10.1016/j.ejmech.2020.112293", "32311607"]}, {"Citation": "Panda S. S. Girgis A. S. Honkanadavar H. H. George R. F. Srour A. M. Synthesis of new ibuprofen hybrid conjugates as potential anti-inflammatory and analgesic agents. Future Med. Chem. 2020;12:1369\u20131386. doi: 10.4155/fmc-2020-0109.", "ArticleIdList": ["10.4155/fmc-2020-0109", "32689823"]}, {"Citation": "Tiwari A. D. Panda S. S. Girgis A. S. Sahu S. George R. F. Srour A. M. La Starza B. Asiri A. M. Hall C. D. Katritzky A. R. Microwave assisted synthesis and QSAR study of novel NSAID acetaminophen conjugates with amino acid linkers. Org. Biomol. Chem. 2014;12:7238\u20137249. doi: 10.1039/c4ob01281j.", "ArticleIdList": ["10.1039/c4ob01281j", "25081868"]}, {"Citation": "Seliem I. A. Panda S. S. Girgis A. S. Nagy Y. I. George R. F. Fayad W. Fawzy N. G. Ibrahim T. S. Al-Mahmoudy A. M. M. Sakhuja R. Abdel-samii Z. K. M. Design, synthesis, antimicrobial and DNA gyrase inhibitory properties of fluoroquinolone-dichloroacetic acid hybrids. Chem. Biol. Drug Des. 2020;95:248\u2013259. doi: 10.1111/cbdd.13638.", "ArticleIdList": ["10.1111/cbdd.13638", "31623026"]}, {"Citation": "Faidallah H. M. Girgis A. S. Tiwari A. D. Honkanadavar H. H. Thomas S. J. Samir A. Kalmouch A. Alamry K. A. Khan K. A. Ibrahim T. S. EL-Mahmoudy A. M. M. Asiri A. M. Pand S. S. Synthesis, antibacterial properties and 2D-QSAR studies of quinolone-triazole conjugates. Eur. J. Med. Chem. 2018;143:1524\u20131534. doi: 10.1016/j.ejmech.2017.10.042.", "ArticleIdList": ["10.1016/j.ejmech.2017.10.042", "29126731"]}, {"Citation": "Panda S. S. Detistov O. S. Girgis A. S. Mohapatra P. P. Samir A. Katritzky A. R. Synthesis and molecular modeling of antimicrobial active fluoroquinolone\u2013pyrazine conjugates with amino acid linkers. Bioorg. Med. Chem. Lett. 2016;26:2198\u20132205. doi: 10.1016/j.bmcl.2016.03.062.", "ArticleIdList": ["10.1016/j.bmcl.2016.03.062", "27025339"]}, {"Citation": "Panda S. S. Girgis A. S. Mishra B. B. Elagawany M. Devarapalli V. Littlefield W. F. Samir A. Fayad W. Fawzy N. G. Srour A. M. Bokhtia R. M. Synthesis, computational studies, antimycobacterial and antibacterial properties of pyrazinoic acid-isoniazid hybrid conjugates. RSC Adv. 2019;9:20450\u201320462. doi: 10.1039/c9ra03380g.", "ArticleIdList": ["10.1039/c9ra03380g", "PMC9065575", "35514723"]}, {"Citation": "Faidallah H. M. Panda S. S. Serrano J. C. Girgis A. S. Khan K. A. Alamry K. A. Therathanakorn T. Meyers M. J. Sverdrup F. M. Eikhoff C. S. Getchell S. G. Katritzky A. R. Synthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates. Bioorg. Med. Chem. 2016;24:3527\u20133539. doi: 10.1016/j.bmc.2016.05.060.", "ArticleIdList": ["10.1016/j.bmc.2016.05.060", "27298002"]}, {"Citation": "Zhou Q. Luo Y. Zhu Y. Chen Q. Qiu J. Cong F. Li Y. Zhang X. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. Eur. J. Med. Chem. 2023;249:115113. doi: 10.1016/j.ejmech.2023.115113.", "ArticleIdList": ["10.1016/j.ejmech.2023.115113", "PMC9830933", "36706621"]}, {"Citation": "El-Sayed N. S. Jureka A. S. Edwards M. R. Lohan S. Williams C. G. Keiser P. T. Davey R. A. Totonchy J. Tiwari R. K. Basler C. F. Parang K. Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. Eur. J. Med. Chem. 2021;226:113862. doi: 10.1016/j.ejmech.2021.113862.", "ArticleIdList": ["10.1016/j.ejmech.2021.113862", "PMC8454092", "34583312"]}, {"Citation": "Seliem I. A. Panda S. S. Girgis A. S. Moatasim Y. Kandeil A. Mostafa A. Ali M. A. Nossier E. S. Rasslan F. Srour A. M. Sakhuja R. Ibrahim T. S. Abdel-samii Z. K. M. Al-Mahmoudy A. M. M. New quinoline-triazole conjugates: synthesis, and antiviral properties against SARS-CoV-2. Bioorg. Chem. 2021;114:105117. doi: 10.1016/j.bioorg.2021.105117.", "ArticleIdList": ["10.1016/j.bioorg.2021.105117", "PMC8219945", "34214752"]}, {"Citation": "Seliem I. A. Girgis A. S. Moatasim Y. Kandeil A. Mostafa A. Ali M. A. Bekheit M. S. Panda S. S. New pyrazine conjugates: synthesis, computational studies, and antiviral properties against SARS-CoV-2. ChemMedChem. 2021;16:3418\u20133427. doi: 10.1002/cmdc.202100476.", "ArticleIdList": ["10.1002/cmdc.202100476", "PMC8426689", "34352160"]}, {"Citation": "Wyman K. A. Girgis A. S. Surapaneni P. S. Moore J. M. Abo Shama N. M. Mahmoud S. H. Mostafa A. Barghash R. F. Juan Z. Dobaria R. D. Almalki A. J. Ibrahim T. S. Panda S. S. Synthesis of potential antiviral agents for SARS-CoV-2 using molecular hybridization approach. Molecules. 2022;27:5923. doi: 10.3390/molecules27185923.", "ArticleIdList": ["10.3390/molecules27185923", "PMC9501548", "36144662"]}, {"Citation": "Hwu J. R. Kapoor M. Gupta N. K. Tsay S.-C. Huang W.-C. Tan K.-T. Hu Y.-C. Lyssen P. Neyts J. Synthesis and antiviral activities of quinazolinamine\u2013coumarin conjugates toward chikungunya and hepatitis C viruses. Eur. J. Med. Chem. 2022;232:114164. doi: 10.1016/j.ejmech.2022.114164.", "ArticleIdList": ["10.1016/j.ejmech.2022.114164", "35176562"]}, {"Citation": "Mishriky N. Asaad F. M. Ibrahim Y. A. Girgis A. S. New 2-pyrazolines of anticipated molluscicidal activity. Pharmazie. 1996;51:544\u2013548.", "ArticleIdList": ["8794465"]}, {"Citation": "Chen M. Cai L. Xiang Y. Zhong L. Shi J. Advances in non-radioactive PSMA-targeted small molecule-drug conjugates in the treatment of prostate cancer. Bioorg. Chem. 2023;141:106889. doi: 10.1016/j.bioorg.2023.106889.", "ArticleIdList": ["10.1016/j.bioorg.2023.106889", "37813074"]}, {"Citation": "Youssef M. A. Panda S. S. Aboshouk D. R. Said M. F. El Taweel A. GabAllah M. Fayad W. Soliman A. A. F. Mostafa A. Fawzy N. G. Girgis A. S. Novel curcumin mimics: design, synthesis, biological properties and computational studies of piperidone\u2013piperazine conjugates. ChemistrySelect. 2022;7:e202201406. doi: 10.1002/slct.202201406.", "ArticleIdList": ["10.1002/slct.202201406"]}, {"Citation": "Al-Hussain S. A. Farghaly T. A. Zaki M. E. A. Abdulwahab H. G. Al-Qurashi N. T. Muhammad Z. A. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity. Bioorg. Chem. 2020;105:104330. doi: 10.1016/j.bioorg.2020.104330.", "ArticleIdList": ["10.1016/j.bioorg.2020.104330", "33038552"]}, {"Citation": "Nafie M. S. Boraei A. T. A. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. Bioorg. Chem. 2022;122:105708. doi: 10.1016/j.bioorg.2022.105708.", "ArticleIdList": ["10.1016/j.bioorg.2022.105708", "35290929"]}, {"Citation": "Zhang C. Xu D. Wang J. Kang C. Efficient synthesis and biological activity of novel indole derivatives as VEGFR-2 tyrosine kinase inhibitors. Russ. J. Gen. Chem. 2017;87:3006\u20133016. doi: 10.1134/S1070363217120465.", "ArticleIdList": ["10.1134/S1070363217120465"]}, {"Citation": "\nhttps://www.drugs.com/history/votrient.html, (accessed on Dec. 11, 2023)"}, {"Citation": "\nhttps://go.drugbank.com/drugs/DB06589, (accessed on Dec. 11, 2023)"}, {"Citation": "Gao G.-R. Li M.-Y. Tong L.-J. Wei L.-X. Ding J. Xie H. Duan W.-H. Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I) Chin. Chem. Lett. 2015;26:1165\u20131168. doi: 10.1016/j.cclet.2015.07.016.", "ArticleIdList": ["10.1016/j.cclet.2015.07.016"]}, {"Citation": "Sana S. Reddy V. G. Bhandari S. Reddy T. S. Tokala R. Sakla A. P. Bhargava S. K. Shankaraiah N. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. Eur. J. Med. Chem. 2020;200:112457. doi: 10.1016/j.ejmech.2020.112457.", "ArticleIdList": ["10.1016/j.ejmech.2020.112457", "32422489"]}, {"Citation": "Ravi K. Dhoddi B. N. Pochampally J. DBU-mediated efficient synthesis of indole-conjugated chromene derivatives and their anticancer evaluation and molecular modeling study. Russ. J. Org. Chem. 2023;59:907\u2013914. doi: 10.1134/S1070428023050214.", "ArticleIdList": ["10.1134/S1070428023050214"]}, {"Citation": "Panda S. S. Girgis A. S. Aziz M. N. Bekheit M. S. Spirooxindole: a versatile niologically active heterocyclic scaffold. Molecules. 2023;28:618. doi: 10.3390/molecules2802061.", "ArticleIdList": ["10.3390/molecules2802061", "PMC9861573", "36677676"]}, {"Citation": "Pandey A. Pandey A. Dubey R. Kant R. Pandey J. Synthesis and computational studies of potent antimicrobial and anticancer indolone scaffolds with spiro cyclopropyl moiety as a novel design element. J. Indian Chem. Soc. 2022;99:100539. doi: 10.1016/j.jics.2022.100539.", "ArticleIdList": ["10.1016/j.jics.2022.100539"]}, {"Citation": "Salem M. A. Ragab A. Askar A. A. El-Khalafawy A. Makhlouf A. H. One-pot synthesis and molecular docking of some new spiropyranindol-2-one derivatives as immunomodulatory agents and in vitro antimicrobial potential with DNA gyrase inhibitor. Eur. J. Med. Chem. 2020;188:111977. doi: 10.1016/j.ejmech.2019.111977.", "ArticleIdList": ["10.1016/j.ejmech.2019.111977", "31927313"]}, {"Citation": "Jarrahpour A. Jowkar Z. Haghighijoo Z. Heiran R. Rad J. A. Sinou V. Rouvier F. Latour C. Brunel J. M. \u00d6zdemir N. Synthesis, in-vitro biological evaluation, and molecular docking study of novel spiro-\u03b2-lactam-isatin hybrids. Med. Chem. Res. 2022;31:1026\u20131034. doi: 10.1007/s00044-022-02898-8.", "ArticleIdList": ["10.1007/s00044-022-02898-8"]}, {"Citation": "Bolous M. Arumugam N. Almansour A. I. Kumar R. S. Maruoka K. Antharam V. C. Thangamani S. Broad-spectrum antifungal activity of spirooxindolo-pyrrolidine tethered indole/imidazole hybrid heterocycles against fungal pathogens. Bioorg. Med. Chem. Lett. 2019;29:2059\u20132063. doi: 10.1016/j.bmcl.2019.07.022.", "ArticleIdList": ["10.1016/j.bmcl.2019.07.022", "31320146"]}, {"Citation": "Moghaddam-Manesh M. Sheikhhosseini E. Ghazanfari D. Akhgar M. Synthesis of novel 2-oxospiro[indoline-3,4\u2032-[1,3]dithiine]-5\u2032-carbonitrile derivatives by new spiro[indoline-3,4\u2032-[1,3]dithiine]@Cu(NO3)2 supported on Fe3O4@gly@CE MNPs as efficient catalyst and evaluation of biological activity. Bioorg. Chem. 2020;98:103751. doi: 10.1016/j.bioorg.2020.103751.", "ArticleIdList": ["10.1016/j.bioorg.2020.103751", "32182517"]}, {"Citation": "Vintonyak V. V. Warburg K. Over B. H\u00fcbel K. Rauh D. Waldmann H. Identification and further development of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B. Tetrahedron. 2011;67:6713\u20136729. doi: 10.1016/j.tet.2011.04.026.", "ArticleIdList": ["10.1016/j.tet.2011.04.026", "20632348"]}, {"Citation": "Borad M. A. Bhoi M. N. Rathwa S. K. Vasava M. S. Patel H. D. Patel C. N. Pandya H. A. Pithawala E. A. Georrge J. J. Microwave-assisted ZrSiO2 catalysed synthesis, characterization and computational study of novel spiro[indole-thiazolidines] derivatives as anti-tubercular agents. Interdiscip. Sci.: Comput. Life Sci. 2018;10:411\u2013418. doi: 10.1007/s12539-016-0195-2.", "ArticleIdList": ["10.1007/s12539-016-0195-2", "27837427"]}, {"Citation": "Borad M. A. Jethava D. J. Bhoi M. N. Patel C. N. Pandya H. A. Patel H. D. Novel isoniazid-spirooxindole derivatives: design, synthesis, biological evaluation, in silico ADMET prediction and computational studies. J. Mol. Struct. 2020;1222:128881. doi: 10.1016/j.molstruc.2020.128881.", "ArticleIdList": ["10.1016/j.molstruc.2020.128881"]}, {"Citation": "Xu J. Xie X. Ye N. Zou J. Chen H. White M. A. Shi P.-Y. Zhou J. Design, synthesis, and biological evaluation of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3\u2032-indoline]-2\u2032,5(3H)-dione analogues as potent NS4B inhibitors for the treatment of dengue virus infection. J. Med. Chem. 2019;62:7941\u20137960. doi: 10.1021/acs.jmedchem.9b00698.", "ArticleIdList": ["10.1021/acs.jmedchem.9b00698", "31403780"]}, {"Citation": "Gollner A. Weinstabl H. Fuchs J. E. Rudolph D. Garavel G. Hofbauer K. S. Karolyi-Oezguer J. Gmaschitz G. Hela W. H. Kerres N. Grondal E. Werni P. Ramharter J. Broeker J. McConnell D. B. Targeted synthesis of complex spiro [3H-indole-3,2\u2019-pyrrolidin]-2(1H)-ones by intramolecular cyclization of azomethine ylides: highly potent MDM2\u2013p53 inhibitors. ChemMedChem. 2019;14:88\u201393. doi: 10.1002/cmdc.201800617.", "ArticleIdList": ["10.1002/cmdc.201800617", "PMC6590160", "30458062"]}, {"Citation": "Espadinha M. Lopes E. A. Marques V. Amaral J. D. dos Santos D. J. V. A. Mori M. Daniele S. Piccarducci R. Zappelli E. Martini C. Rodrigues C. M. P. Santos M. M. M. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors. Eur. J. Med. Chem. 2022;241:114637. doi: 10.1016/j.ejmech.2022.114637.", "ArticleIdList": ["10.1016/j.ejmech.2022.114637", "35961068"]}, {"Citation": "Murali K. Sparkes H. A. Prasad K. J. R. Regio- and stereoselective synthesis of dispirooxindolepyrrolocarbazole hybrids via 1,3-dipolar cycloaddition reactions: cytotoxic activity and SAR studies. Eur. J. Med. Chem. 2018;143:292\u2013305. doi: 10.1016/j.ejmech.2017.11.039.", "ArticleIdList": ["10.1016/j.ejmech.2017.11.039", "29197734"]}, {"Citation": "George R. F. Ismail N. S. M. Stawinski J. Girgis A. S. Design, synthesis and QSAR studies of dispiroindole derivatives as new antiproliferative agents. Eur. J. Med. Chem. 2013;68:339\u2013351. doi: 10.1016/j.ejmech.2013.07.035.", "ArticleIdList": ["10.1016/j.ejmech.2013.07.035", "23994327"]}, {"Citation": "Girgis A. S. Mabied A. F. Stawinski J. Hegazy L. George R. F. Farag H. Shalaby E. M. Ahmed Farag I. S. Synthesis and DFT studies of an antitumor active spiro-oxindole. New J. Chem. 2015;39:8017. doi: 10.1039/c5nj01109d.", "ArticleIdList": ["10.1039/c5nj01109d"]}, {"Citation": "Lopes E. A. Mestre R. Fontinha D. Legac J. Pei J. V. Sanches-Vaz M. Mori M. Lehane A. M. Rosenthal P. J. Prud\u00eancio M. Santos M. M. M. Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity. Eur. J. Med. Chem. 2022;236:114324. doi: 10.1016/j.ejmech.2022.114324.", "ArticleIdList": ["10.1016/j.ejmech.2022.114324", "35390711"]}, {"Citation": "Mathebula B. Butsi K. R. van Zyl R. L. van Vuuren N. C. J. Hoppe H. C. Michael J. P. de Koning C. B. Rousseau A. L. Preparation and antiplasmodial activity of 3',4'-dihydro-1'H-spiro(indoline-3,2'-quinolin)-2-ones. Chem. Biol. Drug Des. 2019;94:1849\u20131858. doi: 10.1111/cbdd.13598.", "ArticleIdList": ["10.1111/cbdd.13598", "31361393"]}, {"Citation": "Kumar R. S. Antonisamy P. Almansour A. I. Arumugam N. Periyasami G. Altaf M. Kim H.-R. Kwon K.-B. Functionalized spirooxindole-indolizine hybrids: stereoselective green synthesis and evaluation of anti-inflammatory effect involving TNF-\u03b1 and nitrite inhibition. Eur. J. Med. Chem. 2018;152:417\u2013423. doi: 10.1016/j.ejmech.2018.04.060.", "ArticleIdList": ["10.1016/j.ejmech.2018.04.060", "29751235"]}, {"Citation": "Hammouda M. B. Boudriga S. Hamden K. Askri M. Knorr M. Strohmann C. Brieger L. Krupp A. Anouar E. Snoussi M. Aouadi K. Kadri A. New spiropyrrolothiazole derivatives bearing an oxazolone moiety as potential antidiabetic agent: design, synthesis, crystal structure, Hirshfeld surface analysis, ADME and molecular docking studies. J. Mol. Struct. 2022;1254:132398. doi: 10.1016/j.molstruc.2022.132398.", "ArticleIdList": ["10.1016/j.molstruc.2022.132398"]}, {"Citation": "Kaur A. Singh B. Vyas B. Silakari O. Synthesis and biological activity of 4-aryl-3-benzoyl-5-phenylspiro[pyrrolidine-2.3'-indolin]-2'-one derivatives as novel potent inhibitors of advanced glycation end product. Eur. J. Med. Chem. 2014;79:282\u2013289. doi: 10.1016/j.ejmech.2014.04.022.", "ArticleIdList": ["10.1016/j.ejmech.2014.04.022", "24747065"]}, {"Citation": "Panda S. S. Aziz M. N. Stawinski J. Girgis A. S. Azomethine ylides\u2013Versatile synthons for pyrrolidinyl-heterocyclic compounds. Molecules. 2023;28:668. doi: 10.3390/molecules28020668.", "ArticleIdList": ["10.3390/molecules28020668", "PMC9866015", "36677727"]}, {"Citation": "Girgis A. S. Panda S. S. Ahmed Farag I. S. El-Shabiny A. M. Moustafa A. M. Ismail N. S. M. Pillai G. G. Panda C. S. Hall C. D. Katritzky A. R. Synthesis, and QSAR analysis of anti-oncological active spiro-alkaloids. Org. Biomol. Chem. 2015;13:1741\u20131753. doi: 10.1039/c4ob02149e.", "ArticleIdList": ["10.1039/c4ob02149e", "25502495"]}, {"Citation": "Girgis A. S. Panda S. S. Srour A. M. Farag H. Ismail N. S. M. Elgendy M. Abdel-Aziz A. K. Katritzky A. R. Rational design, synthesis and molecular modeling studies of novel anti-oncological alkaloids against melanoma. Org. Biomol. Chem. 2015;13:6619\u20136633. doi: 10.1039/c5ob00410a.", "ArticleIdList": ["10.1039/c5ob00410a", "25988330"]}, {"Citation": "Girgis A. S. Panda S. S. Shalaby E. M. Mabied A. F. Steel P. J. Hall C. D. Katritzky A. R. Regioselective synthesis and theoretical studies of an anti-neoplastic fluoro-substituted dispirooxindole. RSC Adv. 2015;5:14780\u201314787. doi: 10.1039/c4ra13433h.", "ArticleIdList": ["10.1039/c4ra13433h"]}, {"Citation": "Girgis A. S. Panda S. S. Aziz M. N. Steel P. J. Hall C. D. Katritzky A. R. Rational design, synthesis, and 2D-QSAR study of anti-oncological alkaloids against hepatoma and cervical carcinoma. RSC Adv. 2015;5:28554\u201328569. doi: 10.1039/c4ra16663a.", "ArticleIdList": ["10.1039/c4ra16663a"]}]}], "History": [{"Year": "2023", "Month": "12", "Day": "31"}, {"Year": "2024", "Month": "1", "Day": "29"}, {"Year": "2024", "Month": "2", "Day": "16", "Hour": "6", "Minute": "44"}, {"Year": "2024", "Month": "2", "Day": "16", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "2", "Day": "16", "Hour": "3", "Minute": "52"}, {"Year": "2024", "Month": "2", "Day": "14"}], "PublicationStatus": "epublish", "ArticleIdList": ["38362086", "PMC10866129", "10.1039/d3ra08962b", "d3ra08962b"]}}]}